NCT03297463 is a Phase 1, PHASE2 clinical trial of Interleukin-2 & Ipilimumab (P-Ib) in Metastatic Melanoma, sponsored by Masonic Cancer Center, University of Minnesota.

Who is sponsoring NCT03297463?

NCT03297463 is sponsored by Masonic Cancer Center, University of Minnesota.

What drugs are being tested in NCT03297463?

Interventions in NCT03297463: Interleukin-2 & Ipilimumab (P-Ib), Interleukin-2 & Ipilimumab (P-II).

What condition does NCT03297463 study?

NCT03297463 studies Metastatic Melanoma, Pulmonary Metastases, Hepatic Metastases, Brain Metastases.

Is NCT03297463 still recruiting?

NCT03297463 is currently withdrawn. Last updated 1 August 2018.

Last reviewed 2018-08-01 · How we verify

NCT03297463

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Withdrawn Phase 1, PHASE2 Last updated 1 August 2018

What this trial tests

Phase 1, PHASE2 trial testing Interleukin-2 & Ipilimumab (P-Ib) in Metastatic Melanoma. Withdrawn.

Timeline

31 January 2018

Primary endpoint
1 February 2020

1 February 2020

Quick facts

Lead sponsor	Masonic Cancer Center, University of Minnesota
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Start date	31 January 2018
Primary completion	1 February 2020
Estimated completion	1 February 2020
Sites	1 location across United States

Drugs / interventions tested

Interleukin-2 & Ipilimumab (P-Ib) — full drug profile →
Interleukin-2 & Ipilimumab (P-II) — full drug profile →

Conditions studied

Metastatic Melanoma — all drugs for Metastatic Melanoma →
Pulmonary Metastases — all drugs for Pulmonary Metastases →
Hepatic Metastases — all drugs for Hepatic Metastases →
Brain Metastases — all drugs for Brain Metastases →

Sponsor

Masonic Cancer Center, University of Minnesota

Who can join

Adults 18 to 85, any sex, with Metastatic Melanoma or Pulmonary Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1b/2 study designed to evaluate combination of the human T-cell cytokine Interleukin-2 (IL-2) and a checkpoint inhibitor Ipilimumab immediately following a course of hypofractionated palliative radiation therapy in the management of unresectable, relapsed/refractory metastatic melanoma.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases.
Tonse R, Tom MC, Mehta MP, Ahluwalia MS, et al · · 2021 · cited 30× · PMID 34359583 · DOI 10.3390/cancers13153682
The biology and therapeutic management of melanoma brain metastases.
Abate-Daga D, Ramello MC, Smalley I, Forsyth PA, et al · · 2018 · cited 23× · PMID 29278675 · DOI 10.1016/j.bcp.2017.12.019
Melanoma brain metastases: review of histopathological features and immune-molecular aspects.
Salvati L, Mandalà M, Massi D. · · 2020 · cited 6× · PMID 32821376 · DOI 10.2217/mmt-2019-0021
Potential dual synergy between electrochemotherapy and sequence of immunotherapies in metastatic melanoma: A case report.
Morgese F, De Feudis F, Balercia P, Berardi R. · · 2023 · cited 2× · PMID 36761389 · DOI 10.3892/mco.2023.2604
Radiotherapy and cytokines: A systems view of immunotherapy and toxicity (Review).
Zhou S, Jiang Y, Fan J, Guo M, et al · · 2026 · PMID 42099233 · DOI 10.3892/ijmm.2026.5848

Verify or expand the search:

Other recruiting trials for Metastatic Melanoma

Currently open trials in the same condition.

NCT06066138 — A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · Phase 1 · recruiting
NCT07237100 — Mirdametinib in Patients With Advanced NF1-mutant Melanoma · Phase 2 · recruiting
NCT07086105 — A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma · Phase 1 · recruiting
NCT07112170 — Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma · NA · recruiting
NCT06488365 — In Vivo Liquid Biopsy of Melanoma (Cytophone) · NA · recruiting

Other Masonic Cancer Center, University of Minnesota trials

Trials by the same sponsor.

NCT06772090 — Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies · NA · not yet recruiting
NCT06584929 — Rural Smoking Cessation · NA · not yet recruiting
NCT07153016 — LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorect · NA · recruiting
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
NCT07070726 — UNTOLD Ovarian Cancer Unmet Needs Survey · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03297463 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota
Last refreshed: 1 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03297463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing